Australian liver-injury alert over 'retatrutide' products

On 19 June 2026 the Victorian Department of Health in Australia issued a health alert: since January, six people had developed acute liver injury after using unapproved injectable products labelled as retatrutide. The pattern of illness suggested a contaminant rather than the drug itself.^[1]

What was announced

The alert was aimed at the public and at doctors. It described a cluster of acute liver injury in adults who had been injecting products sold as retatrutide. Retatrutide has no approval in Australia, as in the UK, so every one of those products came from an unlicensed source. The department's judgement was that liver injury on this scale did not fit what the trials had shown for the drug, and that something else in the vials was the more likely explanation.^[1]

The next day ABC News reported the most serious case. A 32-year-old Melbourne woman developed acute liver failure within a week of two injections in late December 2025. She spent about a month in the Royal Melbourne Hospital, where a liver transplant was discussed and narrowly avoided. Six months on she was still on steroids, had been readmitted more than once and was unable to work. The same report described two women in their twenties treated for liver injury at another Melbourne hospital, and a man in his forties who suffered a major kidney injury from dehydration after diarrhoea around forty times a day.^[3]

The double-strength vial

On 27 June ABC reported the results of testing arranged with the University of Queensland's School of Public Health and an accredited Melbourne laboratory. A vial labelled as 10 mg of retatrutide contained about 19 mg, almost double. Its purity was 16.6%; the rest was probably a filler such as mannitol. A gastroenterologist quoted in the report described a patient losing around eight litres of fluid a day to diarrhoea and needing intravenous fluids.^[2]

The two findings point at two different dangers. A contaminant can injure the liver directly. A vial at double strength delivers twice the intended dose of a drug whose side effects rise steeply with dose. Neither can be seen by looking at the vial.

What is new

Trials of retatrutide found only rare, short-lived rises in liver enzymes, in about 1% of participants in Phase 2.^[4] This was the first cluster of serious liver injury linked to products sold under the drug's name, and the first time a health department had publicly blamed suspected contaminants in "retatrutide" vials. The liver-failure cluster page tracks the cases as they are reported.

What it does not mean

• It does not show that retatrutide itself damages the liver. The department's view was the opposite: the illness looked like something added to the vials. The trial evidence on the liver is on the liver and kidney page.
• It does not mean UK products are different. Nobody knows where any given vial was filled. Independent testing elsewhere has found similar problems; see what is actually in the vials.
• It does not mean only six people were affected. These are the cases that reached hospital and were recognised.